Samir Ounzain, HAYA Therapeutics CEO
May 8, 2025 08:00 AM EDT
Financing
Startups

HAYA Ther­a­peu­tics gets $65M for 'dark genome' work fol­low­ing last year's Lil­ly pact

Kyle LaHucik

Senior Reporter

Af­ter work­ing off $20 mil­lion in seed fund­ing for about four years, HAYA Ther­a­peu­tics tapped the fund­ing well and came back with $65 mil­lion to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Lan­theus culls late-stage Lil­ly-part­nered prostate can­cer ra­di­oli­gand

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Blood can­cer biotech Vor Bio ends clin­i­cal work, lays off 95% of staff

Te­va plans staff cuts as it com­mits to ac­cel­er­at­ing growth

Gilead re­veals plans to put an­oth­er $11B in­to US man­u­fac­tur­ing

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times